DOCSLIB.ORG

General User Charges in AIIMS Raipur

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
General User Charges in AIIMS Raipur General User Charges in AIIMS Raipur S No. Name of General Charges Paying Ward General Remark Ward/OPD 1 Registration Charges 200 25 2 Bed Charges Per Day (Sami 2000 35 Patients being adm Deluxe) itted in 3 Bed Charges Per Day (Deluxe) 3000 35 Paying/General 4 Diet Charges Per Day 200 Optional Nil ward will pay an advance for 10 days charges at the time of admission. 5 ICU/NICU/PICU/CCU Charges 1000 (Above & 300 Per Day Over to Bed Charge 6 Minor Operation in OT/MOT 250 100 not mentioned in list, under L A 7 Minor Operation in OT/MOT 1000 300 not mentioned in list, under G A 8 Major Operation in OT, Not 2000 1000 mentioned in list under G A 9 Medical Certificate (Sickness) 10 10 10 Medical Certificate (Fitness) 10 10 11 Tubectomy / Laparoscopic 25 20 Sterilization 12 Death file charges 25 25 13 Medico Legal Injury Report 50 50 (MLR) 14 Birth / Death Certificate 1st 0 0 Copy 15 Birth / Death Certificate 5 5 Subsequent Copy 16 Additional correction in Birth 10 10 / Death / certificate 17 Completion of LIC / Insurance 50 50 claim file 18 Subsequent Pass if on special 50 50 condition 19 Supply of blood (One Unit) 250 75 1 20 Medical Board Certificate 500 500 On Special Case User Charges for Investigations in AIIMS Raipur S No. Name of Investigations Paying General Remark Ward Ward/OPD Anaesthsia 1 ABG 75 50 2 ABG ALONGWITH 150 100 ELECTROLYTES(NA+,K+)(Na,K) 3 ONLY ELECTROLYTES(Na+,K+,Cl,Ca+) 75 50 4 ONLY CALCIUM 50 25 5 GLUCOSE 25 20 6 LACTATE 25 20 7 UREA. 25 20 8 OSMOLITY 25 20 9 Hb 25 20 10 HCT 25 20 Biochemistry 1 ACID PHOSPHATASE (ACP) 25 25 2 ALKALINE PHOSPHATASE (ALP) -(OPD- 25 25 Patient) 3 AMYLASE 25 25 4 CALCIUM 50 25 5 CHLORIDES (CL-) 25 20 6 BILIRUBIN(CONJUGATED) (D-Bil) -(Opd- 25 25 Patient) 7 CREATININE (OPD-Patient) 25 25 8 CREATININE KINASE-NAC (CK-NAC) 25 25 9 GLUCOSE TOLERANCE TEST (GTT) 250 100 10 INORGANIC PHOSPHORUS (Pi) 25 25 11 LACTATE DEHYDROGENASE (LDH) 50 50 2 12 MAGNESIUM (Mg2+) 50 25 13 POTASSIUM SODIUM-(K+ & NA+) (OPD- 25 25 Patient) 14 ALBUMIN AND GLOBULMIN PROTIENS - 25 25 (OPD-Patient) 15 C-REACTIVE PROTEIN (CRP) 50 25 16 SERUM IRON 25 25 17 ALANINE TRANSAMINASE/ASPARTATE 25 25 TRANSAMINASE-ALT/AST SGPT/SGOT- (OPD-Patient) 18 BILIRUBIN TOTAL (T-BIL) (OPD-Patient) 25 25 19 TOTAL CHOLESTEROL 25 25 20 TOTAL PROTIEN 25 20 21 TRIGLYCERIDES (TG) -(OPD-Patient) 50 50 22 UREA 25 20 23 URIC ACID 50 25 24 TRIGLYCERIDES (TG)-(IN- Patient) 25 20 25 Hdl Cholesterol(In-Patient) 25 20 26 ALKALINE PHOSPHATASE (ALP) -(IN- 25 20 Patient) 27 ALANINETRANSAMINASE/ASPARTATE 25 20 TRANSAMINASE-ALT/AST SGPT/SGOT - (IN-Patient) 28 BILIRUBIN TOTAL (T-BIL) -(IN-Patient) 25 20 29 CREATININE (IN- Patient) 25 20 30 POTASSIUM & SODIUM (K+ & NA+)-(IN- 25 20 Patient) 31 GLUCOSE (RBS/ FBS) 25 20 32 LIPASE 100 50 33 BENCE JONES PROTEINS URINARY (BJP) 25 25 34 URINARY CHLORIDES (24 HRS. 25 25 QUANTITATIVE) 3 35 URINARY CREATININE (24 HRS. 25 25 QUANTITATIVE 36 URINARY GLUCOSE (QUANTITATIVE) 10 10 37 URINARY PHOSPHORUS (24 HRS 25 25 QUANTITATIVE) 38 URINARY SODIUM AND/OR POTASIUM 25 25 (QUANTITATIVE) 39 URINE ALBUMIN (24 HRS QUANTITATIVE) 25 25 40 URINE CALCIUM (24HRS QUANTITATIVE)) 25 25 41 URINE UROBILINOGEN (QUALITATIVE) 50 50 42 CHYLOMICRONS 10 10 43 CSF CHLORIDES 10 10 44 CSF GLUCOSE 25 25 45 CSF PROTEIN 25 25 46 SWEAT CHLORIDE ESTIMATION 50 50 47 CREATINE KINASE(CK-MB) 200 100 48 PLASMA LP(a) 150 100 49 LIPID PROFILE (OPD-Patient) 200 100 50 ARSENLIC (Blood, Urine, Nails, Hair) 250 100 51 URINARY PROPHOBILINOGEN/ 100 50 UROBILINOGEN (QUALITATIVE) 52 STOOL OCCULT BLOOD (OB) 250 125 53 PSA 200 100 54 ALCOHOL 200 100 55 APOLOPOPROTEIN A-I (APO AI) 200 100 56 APOLOPOPROTEIN B (APO B) 250 125 57 C3 250 125 58 C4 250 125 59 MYOGLOBIN 300 150 4 60 RHEUMATOID FACTOR (Rh) 300 150 61 GAMMA GLUTAMYL TRANSFERASE (GGT) 100 50 62 BILIRUBIN(CONJUGATED) (D-Bil) -(In- 25 20 Patient) 63 ALBUMIN AND GLOBULMIN PROTIENS - 25 20 (IN-Patient) 64 URINARY URIC ACID 24 HRS. 50 25 65 URINARY MAGNESIUM 24 HRS 50 25 66 URINARY UREA 24 HRS. 25 25 67 URINARY VMA (24 HRS.) 800 400 68 URINARY SPOT SODIUM (Na+) Potassium 50 25 (k+) CHLORIDE(CL-) 69 URINARY SODIUM (Na+) Potassium (k+) 50 25 CHLORIDE(CL-)(24 HRS.) 70 TOTAL CHOLESTEROL (IN-Patient) 25 20 71 LIPID PROFILE (IN-Patient) 25 20 72 HCG 200 100 73 AFP. 500 250 74 CA 125. 500 250 75 CA 15.3 500 250 76 CA 19.9 500 250 77 CEA . 500 250 78 FERRITIN 200 100 79 RBC FOLATE 200 100 80 FOLATE 200 100 81 VITAMIN B12 200 100 82 PRO BNP 600 300 83 TROPONIN T 200 100 84 FREE PSA (TOTAL/ FREE PSA) 200 100 85 COPPER(CU) 250 100 86 ZINC(ZN) 250 100 87 LEAD (BLOOD/URINE). 250 100 88 SELENIUM 250 100 89 MERCURY 250 100 90 CERULOPLASMIN 150 75 5 91 CHROMIUM 250 100 92 LIVER FUNCTION TEST(LFT)(ALP D-BIL T- 250 200 BIL ALT/AST ALBUMIN & GLOBULMIN PROTIENS TOTAL PROTEIN) 93 SERUM/ PLASMA OSMOLALITY 250 125 94 URINE OSMOLALITY. 250 125 95 RANDOM GLUCOSE 25 20 96 FASTING GLUCOSE 25 20 97 DUMMY(INFECT) 25 20 Biophysics 1 14c-Urea Breath Test 300 200 2 FTIR ANALYSIS OF RENAL/ GALL STONES 200 100 1 ECHO/TEE 100 100 2 EXERCISE TMT 200 100 3 TILT TEST 500 150 Centre Sophisticated Intrument Cell 1 FLOW CYTOMETER (Sample Acquistion 50 25 per tube) 2 REAL-TIME PCR-96 WELL PLATE (per 2000 500 Plate) 3 REAL-TIME PCR-COVERING FOIL (per Foil) 400 100 4 REAL-TIME PCR 2700 1500 5 SIMPLE PCR 1000 500 6 2-D ELECTROPHORESIS(Include PH 800 800 STRIP) PER SAMPLE 7 DHPLC Sample Analysis(per Sample) 100 25 8 FLOW CYTOMETER (Sample Sorting per 2000 500 Sample) 9 REAL-TIME PCR-8 well Strip(per Strip) 200 50 6 10 HPLC Sample Analysis (per Sample) 400 100 11 FPLC Sample Analysis(per Sample) 400 100 12 AUTOMATED DNA SEQUENCER(per 500 350 Reaction) 13 MALDI TOF/TOF Instrument uses (per 1200 300 Hour) 14 MALDI TOF/TOF Sample processing in Gel 1000 250 (per Sample) 15 MALDI TOF/TOF Sample processing in 200 50 Solution (per Sample) Cytology 1 BUCCAL SMEAR FOR SEX CHROMATIN 25 25 2 ESTROGEN RECEPTOR 900 270 3 IMMUNOCYTOCHEMISTRY (Per Antibody) 500 300 4 IMMUNOCYTOCHEMISTRY ( 5 Antibody) 2500 1500 5 PROGESTERON RECEPTOR 900 270 6 HPV TESTING 1600 800 7 CYTOPATHOLOGY FNA 100 100 8 FLOCYTOMETRIC IMMUNOPHENOTYPING 500 300 (1 Antibody) 9 FLOCYTOMETRIC IMMUNOPHENOTYPING 3000 1500 (5 Antibody) 10 CERVICAL SMEAR (PAP SMEAR) 200 100 11 GYNAEC-HISTOPATHOLOGY (BIOPSY) 250 100 12 LIQUID BASED CYTOLOGY (LBC) 200 100 13 EXFOLIATIVE CYTOLOGY (MALIGLANT 100 100 CYTOLOGY) 7 14 IHC-I (UPTO 2 ANTIBODIES)-IHC 500 500 (IMMUNO CHEMISTRY) 15 IHC-II (UPTO 3-5 ANTIBODIES)-IHC 1500 1500 (IMMUNO CHEMISTRY) 16 IHC-III ( MORE THAN 5 ANTIBODIES)- 2500 2500 IHC(IMMUNO CHEMISTRY) 17 FISH 4000 2000 18 BLOCKS/ SLIDES FOR OPINION/ REVIEW 500 500 (UPTO 2 BLOCKS)INCLUDING CELL BLOCK 19 BLOCKS/ SLIDES FOR OPINION/ REVIEW 1000 1000 (3 OR MORE BLOCKS) 20 ISSUE OF PARAFFIN BLOCKS -(SECURITY 1000 1000 RETURN) 21 ISSUE OF DUPLICATE UNSTAINED SLIDES 200 200 (UPTO 2SLIDES) 22 ISSUE OF DUPLICATE UNSTAINED SLIDES 500 500 (MORETHAN 2 SLIDES) 23 Dummy cytology 25 20 Endocrinology 1 TSH 200 100 2 T3 & T4 200 100 3 T3 & T4 & TSH 300 200 4 CORTISOL-AM/PM OVERNIGHT 225 150 5 CORTISOL-POST DEXA 115 75 6 CORTISOL-LOW DOSE 115 75 7 CORTISOL-HIGH DOSE 115 75 8 CORTISOL-ACTH STIMULATION 450 300 9 CORTISOL-ITT 565 375 10 TESTOSTERONE BASAL 300 200 11 RESP TO HCG STIMULATION 900 600 12 E2-17 B 225 150 8 13 DHT 300 200 14 PROGESTERONE 300 200 15 GROWTH HORMONE-BASAL 115 75 16 GROWTH HORMONE-RESP TO ITT/Ggt 565 375 17 INSULIN - BASAL 150 100 18 LH & FSH 450 300 19 PRL (PROLACTIN) 225 150 20 HbA1c 250 100 21 PLANTER PRESSURE STUDIES 100 50 22 CORTISOL 250 125 23 INSULIN 250 125 24 C-PEPTIDE 500 250 25 PTH 400 200 26 ACTH 400 200 27 25(OH)D 700 350 28 A-TPO 300 150 29 TG 500 250 30 PLASMA OSMOLALITY 250 125 31 URINE OSMOLALITY 250 125 32 T3 100 50 33 T4 100 50 34 LH 225 150 35 FSH 225 150 36 DHEAS 500 250 37 Procalcitonin (Pct) 1500 750 38 INSULIN TOLERANCE TEST - GH (0 30 60 2000 1500 90 MIN) 39 INSULIN TOLERANCE TEST- CORTISOL (0 2000 1500 60 120 MIN)- 40 GH-OGTT TEST - GH (0 60 120 MIN) 500 350 41 GLUCAGON -C- PEPTIDE TEST - C-PEPTIDE 1500 1000 (-15 0 6 MIN) 42 SYNACTHEN STIMULATION TEST- 750 500 CORTISOL (0 30 60 MIN) 43 GnrH STIMULATION TEST - LH (0 AND AT 750 500 120 MIN) 9 44 HCG STIMULATION TEST - LH 1500 1000 TESTOSTERONE (0 HRS) 45 HCG STIMULATION TEST - 1500 1000 TESTOSTERONE (72 HRS) 46 WATER DEPRIVATION TEST - SERUM 2000 1500 OSMOLALITY 47 WATER DEPRIVATION TEST - URINE 2000 1500 OSMOLALITY 48 ANTI-GAD65 ANTI-IA2 ANTI-INSULIN 3000 1500 49 ANTI-THYROGLOBULIN (ANTI-TG) 700 350 50 ANTI MULLERIAN HORMONE (AMH) 2000 1000 51 BETA-CROSS LAPS 1000 500 52 N-MID OSTEOCALCIN 1000 500 53 PINP 1000 500 54 PKG-HBAIC VPT ABI MICROALBUMINURIA 600 300 FUNDUS EXAMINATION 55 ANTI-GAD65 1000 500 56 ANTI-IA2 1000 500 57 ANTI-INSULIN 1000 500 Gastroenterology 1 HBsAg ELISA 100 50 2 ANTI HBc IgM ELISA 300 150 3 ANTI HBc TOTAL ELISA 300 150 4 HBeAg/ ANTI HBc AB ELISA 300 150 5 ANTI HCV ELISA 200 100 6 ANTI HDC IgM/ IgG ELISA 300 150 7 ANTI HAV IgM/ IgG ELISA 300 150 8 ANTI HEV IgM/ IgG ELISA 300 150 9 ROTA VIRUS Ag ELISA 300 200 10 ANTI CMV IgM/ IgG ELISA 150 100 11 ENDOSONOGRAPHY (EUS) 250 100 12 INTRADUCTAL ULTRASOUND/ CATHETER 500 250 EUS (IDUS) 13 CALPROTECTIN ASSAY 700 350 10 14 CMV PP 65 ANTIGEN (Ag) ELISA 325 250 15 ANTI HSV 1 IgM ELISA 225 150 16 ANTI HSV 2 IgM ELISA 225 150 17 HSV 1 ANTIGEN(Ag)ELISA 325 250 18 HSV 2 ANTIGEN(Ag) ELISA 325 250 Hematology 1 ANTENATAL DIAGNOSIS OF 6000 4000 THALASSEMIA 2 ANTI-THROMBIN-III ASSAY 600 500 3 AUTO HAEMOLYSIS 150 100 4 BLEEDING TIME (BT) 30 30 5 BONE MARROW/ BLOOD CELL 50 50 CYTOCHEMISTRY (PER STAIN) 6 PERIPHERAL SMEAR (BLOOD FILM 50 50 MORPHOLOGY) (OPD-Patient) 7 BONE MARROW ASPIRATION AND 600 400 TREPHINE BIOPSY 8 BONE MARROW ASPIRATION ONLY 300 200 9 CYTOGENETIC STUDY FROM PERIPHERAL 1000 500 BLOOD/BONE MARROW 10 CLOT RETRACTION TIME 25 25 11 CLOTTING TIME 10 10 12 COOMBS' TEST 200 100 13 CORRECTION STUDIES IN COAGULATION 375 250 14 ERYTHROCYTE SEDIMENTATION RATE 25 20 (ESR) 15 FDPs/FIBRIN MONOMERS 75 75 16 FOETAL HAEMOGLOBIN 25 20 17 G6PD SCREENING TEST 50 30 18 HAM'S TEST 150 100 11 19 COMPLETE BLOOD COUNT 50 50 (CBC)/(HEMOGRAM (HB TLC PLATELET COUNT RBC/RED CELL INDICES) 20 HEINZ BODIES 25 25 21 HESS TEST 30 30 22 INCUBATED OSMOTIC FRAGILITY (RBC) 25 25 23 L.E.
Load more

Recommended publications
  • BREAST IMAGING for SCREENING and DIAGNOSING CANCER Policy Number: DIAGNOSTIC 105.9 T2 Effective Date: January 1, 2017
    Oxford UnitedHealthcare® Oxford Clinical Policy BREAST IMAGING FOR SCREENING AND DIAGNOSING CANCER Policy Number: DIAGNOSTIC 105.9 T2 Effective Date: January 1, 2017 Table of Contents Page Related Policies INSTRUCTIONS FOR USE .......................................... 1 Omnibus Codes CONDITIONS OF COVERAGE ...................................... 1 Preventive Care Services BENEFIT CONSIDERATIONS ...................................... 2 Radiology Procedures Requiring Precertification for COVERAGE RATIONALE ............................................. 3 eviCore Healthcare Arrangement APPLICABLE CODES ................................................. 5 DESCRIPTION OF SERVICES ...................................... 6 CLINICAL EVIDENCE ................................................. 7 U.S. FOOD AND DRUG ADMINISTRATION ................... 16 REFERENCES .......................................................... 18 POLICY HISTORY/REVISION INFORMATION ................ 22 INSTRUCTIONS FOR USE This Clinical Policy provides assistance in interpreting Oxford benefit plans. Unless otherwise stated, Oxford policies do not apply to Medicare Advantage members. Oxford reserves the right, in its sole discretion, to modify its policies as necessary. This Clinical Policy is provided for informational purposes. It does not constitute medical advice. The term Oxford includes Oxford Health Plans, LLC and all of its subsidiaries as appropriate for these policies. When deciding coverage, the member specific benefit plan document must be referenced. The terms
    [Show full text]
  • Breast Scintimammography
    CLINICAL MEDICAL POLICY Policy Name: Breast Scintimammography Policy Number: MP-105-MD-PA Responsible Department(s): Medical Management Provider Notice Date: 11/23/2020 Issue Date: 11/23/2020 Effective Date: 12/21/2020 Next Annual Review: 10/2021 Revision Date: 09/16/2020 Products: Gateway Health℠ Medicaid Application: All participating hospitals and providers Page Number(s): 1 of 5 DISCLAIMER Gateway Health℠ (Gateway) medical policy is intended to serve only as a general reference resource regarding coverage for the services described. This policy does not constitute medical advice and is not intended to govern or otherwise influence medical decisions. POLICY STATEMENT Gateway Health℠ does not provide coverage in the Company’s Medicaid products for breast scintimammography. The service is considered experimental and investigational in all applications, including but not limited to use as an adjunct to mammography or in staging the axillary lymph nodes. This policy is designed to address medical necessity guidelines that are appropriate for the majority of individuals with a particular disease, illness or condition. Each person’s unique clinical circumstances warrant individual consideration, based upon review of applicable medical records. (Current applicable Pennsylvania HealthChoices Agreement Section V. Program Requirements, B. Prior Authorization of Services, 1. General Prior Authorization Requirements.) Policy No. MP-105-MD-PA Page 1 of 5 DEFINITIONS Prior Authorization Review Panel – A panel of representatives from within the Pennsylvania Department of Human Services who have been assigned organizational responsibility for the review, approval and denial of all PH-MCO Prior Authorization policies and procedures. Scintimammography A noninvasive supplemental diagnostic testing technology that requires the use of radiopharmaceuticals in order to detect tissues within the breast that accumulate higher levels of radioactive tracer that emit gamma radiation.
    [Show full text]
  • Research Article Magnetic Resonance Sialography Findings of Submandibular Ducts Imaging
    Hindawi Publishing Corporation BioMed Research International Volume 2013, Article ID 417052, 6 pages http://dx.doi.org/10.1155/2013/417052 Research Article Magnetic Resonance Sialography Findings of Submandibular Ducts Imaging Nezahat Karaca ErdoLan,1 Canan Altay,2 Nesibe Özenler,3 TuLba Bozkurt,1 Engin Uluç,1 Berna Dirim Mete,1 and Esmail Özdemir4 1 Department of Radiology, Izmir Ataturk¨ Research and Training Hospital, Basın Sitesi, Karabaglar,˘ 35360 Izmir, Turkey 2 Department of Radiology, Medical School, Dokuz Eylul University, Inciralti, 35340 Izmir, Turkey 3 Department of Radiology, Balıkesir Ataturk¨ State Hospital, Yıldız Mahallesi Soma Caddesi No. 1, 10100 Balıkesir, Turkey 4 Universal Ege Health Hospital, 35220 Izmir, Turkey Correspondence should be addressed to Canan Altay; [email protected] Received 2 April 2013; Revised 29 May 2013; Accepted 12 June 2013 Academic Editor: Yoshito Tsushima Copyright © 2013 Nezahat Karaca Erdogan˘ et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Purpose. We aimed to assess the problem solving capability of magnetic resonance sialography (MR sialography), a noninvasive method for imaging submandibular gland ducts and determining duct-related pathologies, by comparing diseased and healthy cases. Materials and Methods. We conducted radiological assessment on a total of 60 submandibular glands (mean age 44.7) in 20 cases and 10 volunteers. MR sialography examinations were conducted with single-shot fast spin-echo sequence by using a surface coil placed on the submandibular gland. Each gland was evaluated in terms of the length, width and stricture of the main duct, as well as the difference between the intraparenchymal duct width, and the main duct width.
    [Show full text]
  • Procedure Guideline for Breast Scintigraphy
    Procedure Guideline for Breast Scintigraphy Iraj Khalkhali, Linda E. Diggles, Raymond Taillefer, Penny R. Vandestreek, Patrick J. Peller and Hani H. Abdel-Nabi Harbor-UCLA Medical Center, Terranee; Nuclear Imaging Consultants, Roseville, California; Hospital Hôtel-Dieu de Montreal, Montreal, Quebec, Canada; Lutheran General Hospital, Park Ridge, Illinois; and University of Buffalo, Buffalo, New York Key Words: breast scintigraphy;procedureguideline should be available, as well as sonograms, if J NucíMed 1999; 40:1233-1235 obtained. 2. A breast physical examination must be performed by either the nuclear medicine physician or the PART I: PURPOSE referring physician. 3. The time of last menses and pregnancy and lactat- The purpose of this guideline is to assist nuclear medicine ing status of the patient should be determined. practitioners in recommending, performing, interpreting and reporting the results of 99mTc-sestamibi breast scintigraphy 4. Breast scintigraphy should be delayed at least 2 wk after cyst or fine-needle aspiration, and 4—6wk (mammoscintigraphy, scintimammography). after core or excisional biopsy. 5. The nuclear medicine physician should be aware of PART II: BACKGROUND INFORMATION AND DEFINITIONS physical signs and symptoms and prior surgical procedures or therapy. Breast scintigraphy is performed after intravenous admin istration of "mTc-sestamibi and includes planar and/or C. Precautions None SPECT. D. Radiopharmaceutical 1. Intravenous injection of 740-1110 MBq (20-30 PART III: COMMON INDICATIONS AND APPLICATIONS mCi) 99mTc-sestamibi should be administered in an A. Evaluate breast cancer in patients in whom mammog- arm vein contralateral to the breast with the sus raphy is not diagnostic or is difficult to interpret (e.g., pected abnormality.
    [Show full text]
  • A Molecular Approach to Breast Imaging
    Journal of Nuclear Medicine, published on January 16, 2014 as doi:10.2967/jnumed.113.126102 FOCUS ON MOLECULAR IMAGING A Molecular Approach to Breast Imaging Amy M. Fowler Department of Radiology, University of Wisconsin–Madison, Madison, Wisconsin malignant cells. A recent meta-analysis of the accuracy of 99mTc-sestamibi scintimammography as an adjunct to di- Molecular imaging is a multimodality discipline for noninvasively agnostic mammography for detection of breast cancer dem- visualizing biologic processes at the subcellular level. Clinical applications of radionuclide-based molecular imaging for breast onstrated a sensitivity of 83% and specificity of 85% (2). cancer continue to evolve. Whole-body imaging, with scinti- However, sensitivity was less for nonpalpable (59%) versus mammography and PET, and newer dedicated breast imaging palpable lesions (87%) despite comparable specificity, with systems are reviewed. The potential clinical indications and the no significant difference between planar and SPECT meth- challenges of implementing these emerging technologies are ods. Decreased sensitivity for nonpalpable, presumably presented. smaller, lesions is in part due to the limited spatial resolu- Key Words: molecular imaging; oncology; breast; PET; PET/ tion of conventional g cameras. CT; radiopharmaceuticals; breast cancer; breast-specific g im- In addition to 99mTc-sestamibi, the positron-emitting ra- aging; positron-emission mammography; positron-emission to- diopharmaceutical 18F-FDG accumulates in many types of mography cancer including breast. Meta-analyses of the accuracy of J Nucl Med 2014; 55:1–4 whole-body 18F-FDG PET used after standard diagnostic DOI: 10.2967/jnumed.113.126102 workup for patients with suspected breast lesions demon- strated sensitivities of 83%–89% and specificities of 74%– 80% (3,4).
    [Show full text]
  • Sl.No CGHS Treatment Procedure/Investigation List Rates for Non NABH Rates for NABH CGHS Bengaluru Rate List
    CGHS Bengaluru Rate List Sl.No CGHS Treatment Procedure/Investigation Rates for Non Rates for List NABH NABH 1 Consultation OPD 135 135 2 Consultation- for Inpatients 270 270 3 Dressings of wounds 45 52 4 Suturing of wounds with local anesthesia 108 124 5 Aspiration Plural Effusion - Diagnostic 120 138 6 Aspiration Plural Effusion - Therapeutic 174 200 7 Abdominal Aspiration - Diagnostic 330 380 8 Abdominal Aspiration - Therapeutic 414 476 9 Pericardial Aspiration 342 393 10 Joints Aspiration 285 329 11 Biopsy Skin 207 239 12 Removal of Stitches 36 41 13 Venesection 124 143 14 Phimosis Under LA 1180 1357 15 Sternal puncture 173 199 16 Injection for Haemorrhoids 373 428 17 Injection for Varicose Veins 315 363 18 Catheterisation 425 500 19 Dilatation of Urethra 450 518 20 Incision & Drainage 378 435 21 Intercostal Drainage 125 144 22 Peritoneal Dialysis 1319 1517 TREATMENT PROCEDURE SKIN 23 Excision of Moles 311 357 24 Excision of Warts 279 321 25 Excision of Molluscum contagiosum 117 135 26 Excision of Veneral Warts 144 166 27 Excision of Corns 126 145 28 I/D Injection Keloid 97 112 29 Chemical Cautery (s) 99 114 TREATMENT PROCEDURE OPTHALMOLOGY 30 66 76 eyes Subconjunctival/subtenon’s injections in one 31 132 152 eyes 32 PterygiumSubconjunctival/subtenon’s Surgery injections in both 5550 6325 33 Conjunctival Peritomy 58 67 34 Conjunctival wound repair or exploration 3300 3795 following blunt trauma 35 Removal of corneal foreign body 115 132 36 Cauterization of ulcer/subconjunctival injection 69 79 in one eye 37 Cauterization of ulcer/subconjunctival
    [Show full text]
  • Evaluation of Nipple Discharge
    New 2016 American College of Radiology ACR Appropriateness Criteria® Evaluation of Nipple Discharge Variant 1: Physiologic nipple discharge. Female of any age. Initial imaging examination. Radiologic Procedure Rating Comments RRL* Mammography diagnostic 1 See references [2,4-7]. ☢☢ Digital breast tomosynthesis diagnostic 1 See references [2,4-7]. ☢☢ US breast 1 See references [2,4-7]. O MRI breast without and with IV contrast 1 See references [2,4-7]. O MRI breast without IV contrast 1 See references [2,4-7]. O FDG-PEM 1 See references [2,4-7]. ☢☢☢☢ Sestamibi MBI 1 See references [2,4-7]. ☢☢☢ Ductography 1 See references [2,4-7]. ☢☢ Image-guided core biopsy breast 1 See references [2,4-7]. Varies Image-guided fine needle aspiration breast 1 Varies *Relative Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate Radiation Level Variant 2: Pathologic nipple discharge. Male or female 40 years of age or older. Initial imaging examination. Radiologic Procedure Rating Comments RRL* See references [3,6,8,10,13,14,16,25- Mammography diagnostic 9 29,32,34,42-44,71-73]. ☢☢ See references [3,6,8,10,13,14,16,25- Digital breast tomosynthesis diagnostic 9 29,32,34,42-44,71-73]. ☢☢ US is usually complementary to mammography. It can be an alternative to mammography if the patient had a recent US breast 9 mammogram or is pregnant. See O references [3,5,10,12,13,16,25,30,31,45- 49]. MRI breast without and with IV contrast 1 See references [3,8,23,24,35,46,51-55].
    [Show full text]
  • Clinical Pathology, Immunopathology and Advanced Vaccine Technology in Bovine Theileriosis: a Review
    pathogens Review Clinical Pathology, Immunopathology and Advanced Vaccine Technology in Bovine Theileriosis: A Review Onyinyechukwu Ada Agina 1,2,* , Mohd Rosly Shaari 3, Nur Mahiza Md Isa 1, Mokrish Ajat 4, Mohd Zamri-Saad 5 and Hazilawati Hamzah 1,* 1 Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, Universiti Putra Malaysia, Serdang 43400, Malaysia; [email protected] 2 Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, University of Nigeria Nsukka, Nsukka 410001, Nigeria 3 Animal Science Research Centre, Malaysian Agricultural Research and Development Institute, Headquarters, Serdang 43400, Malaysia; [email protected] 4 Department of Veterinary Pre-clinical sciences, Faculty of Veterinary Medicine, Universiti Putra Malaysia, Serdang 43400, Malaysia; [email protected] 5 Research Centre for Ruminant Diseases, Faculty of Veterinary Medicine, Universiti Putra Malaysia, Serdang 43400, Malaysia; [email protected] * Correspondence: [email protected] (O.A.A.); [email protected] (H.H.); Tel.: +60-11-352-01215 (O.A.A.); +60-19-284-6897 (H.H.) Received: 2 May 2020; Accepted: 16 July 2020; Published: 25 August 2020 Abstract: Theileriosis is a blood piroplasmic disease that adversely affects the livestock industry, especially in tropical and sub-tropical countries. It is caused by haemoprotozoan of the Theileria genus, transmitted by hard ticks and which possesses a complex life cycle. The clinical course of the disease ranges from benign to lethal, but subclinical infections can occur depending on the infecting Theileria species. The main clinical and clinicopathological manifestations of acute disease include fever, lymphadenopathy, anorexia and severe loss of condition, conjunctivitis, and pale mucous membranes that are associated with Theileria-induced immune-mediated haemolytic anaemia and/or non-regenerative anaemia.
    [Show full text]
  • Evaluation of the Quantitative Accuracy of a Commercially-Available Positron Emission Mammography Scanner
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 8-2010 EVALUATION OF THE QUANTITATIVE ACCURACY OF A COMMERCIALLY-AVAILABLE POSITRON EMISSION MAMMOGRAPHY SCANNER Adam Springer Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Diagnosis Commons, Equipment and Supplies Commons, and the Other Medical Sciences Commons Recommended Citation Springer, Adam, "EVALUATION OF THE QUANTITATIVE ACCURACY OF A COMMERCIALLY-AVAILABLE POSITRON EMISSION MAMMOGRAPHY SCANNER" (2010). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 64. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/64 This Thesis (MS) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. EVALUATION OF THE QUANTITATIVE ACCURACY OF A COMMERCIALLY- AVAILABLE POSITRON EMISSION MAMMOGRAPHY SCANNER
    [Show full text]
  • Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency
    Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck.
    [Show full text]
  • Microbiology and Immunology
    College of Medicine MI Microbiology and Immunology MI 494G IMMUNOBIOLOGY. (3) A survey of theories and mechanisms of immunity, including: nature of antigens and antibodies, antigen-antibody reactions, immunocompetent cells, immunogenetics, allergic reactions, tumor immunology and transplantation immunology. Prereq: BCH 401G (may be taken concurrently) and BIO 208 or BIO 308 or consent of instructor. (Same as BIO 494G.) MI 590 CELLULAR AND MOLECULAR PHYSIOLOGY. (4) This course will focus on the cellular and molecular physiology of inter-and intracellular communication. In particular, it will provide an overview of established and emerging intracellular signaling mechanisms which utilize i) cyclic nucleotides (cAMP; cGMP), ii) calcium (phosphatidylinositol metabolism: cyclic ADP-ribose), iii) transmembrane ion fluxes (voltage- and receptor-operated channels), iv) tyrosine kinases, and v) nuclear transcription factors. The material will be presented in a number of formats including didactic lecture and group discussions of selected readings. Prereq: PGY 412G, PGY 502 or consent of instructor. (Same as PGY 590.) MI 595 IMMUNOBIOLOGY LABORATORY. (2) Laboratory in immunology and serology. Preparation, standardization, and uses of biological products; serology. Laboratory; four hours. Prereq: BIO/MI 494G or concurrently; or consent of instructor. (Same as BIO 595.) MI 598 CLINICAL MICROBIOLOGY. (3) An introduction to the concepts of clinical microbiology through a survey of the microbial diseases of man using an organ system approach. Prereq: BIO 208 and 209, BIO 476G recommended, CHE 230 or 236, or consent of instructor. (Same as PAT 598.) MI 601 SPECIAL TOPICS IN MOLECULAR AND CELLULAR GENETICS. (1) Each semester five distinguished scientists visit the UK campus to deliver a series of three formal lectures each and participate in numerous informal contacts with graduate students.
    [Show full text]
  • Procedure Codes for Physician: Radiology
    NEW YORK STATE MEDICAID PROGRAM PHYSICIAN - PROCEDURE CODES SECTION 4 - RADIOLOGY Physician – Procedure Codes, Section 4 - Radiology Table of Contents GENERAL INSTRUCTIONS ............................................................................................................ 4 GENERAL RULES AND INFORMATION ......................................................................................... 6 MMIS RADIOLOGY MODIFIERS .................................................................................................... 8 DIAGNOSTIC RADIOLOGY (DIAGNOSTIC IMAGING)................................................................. 9 HEAD AND NECK.................................................................................................................... 9 CHEST .................................................................................................................................. 10 SPINE AND PELVIS .............................................................................................................. 11 UPPER EXTREMITIES .......................................................................................................... 12 LOWER EXTREMITIES ......................................................................................................... 13 ABDOMEN ............................................................................................................................ 14 GASTROINTESTINAL TRACT ............................................................................................... 15 URINARY
    [Show full text]